(Q38109095)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

0 references

Sylvain Drouot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Aurélie Barrail-Tran

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

815-831

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23703578%20AND%20SRC:MED&resulttype=core&format=json

HMG-CoA reductase inhibitors and myotoxicity

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Polypharmacy in the elderly: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

How to optimize HCV therapy in genotype 1 patients: management of side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Isoprenoid metabolism and the pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Differential metabolic effects of distinct statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

A systematic review and meta-analysis on the therapeutic equivalence of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Molecular biology of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

21 January 2018

Statin induced myopathy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statin induced myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statins for renal patients: a fiddler on the roof?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statin-associated adverse cognitive effects: survey results from 171 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statin drug interactions and related adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Clinical pharmacokinetics of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacogenetics of antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Treatment of HIV infection with once-daily regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Drug uptake transporters in antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Pitavastatin: efficacy and safety in intensive lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0075-4

Statin induced proteinuria: renal injury or renoprotection?

21 January 2018

1 reference

12 December 2020

Regulation of HMG-CoA reductase

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Oral absorption of the HIV protease inhibitors: a current update

1 reference

12 December 2020

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

12 December 2020

Clinical pharmacokinetics of statins

1 reference

12 December 2020

Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin

1 reference

12 December 2020

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients

1 reference

12 December 2020

An assessment of statin safety by hepatologists

1 reference

12 December 2020

Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir

1 reference

12 December 2020

Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir

1 reference

12 December 2020

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

12 December 2020

1 reference

12 December 2020

Rhabdomyolysis due to probable interaction between simvastatin and ritonavir

1 reference

12 December 2020

Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.

1 reference

12 December 2020

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

1 reference

12 December 2020

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results

1 reference

12 December 2020

The role of statins in chronic kidney disease

1 reference

12 December 2020

Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection

1 reference

12 December 2020

Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.

1 reference

12 December 2020